Ann: FY22 results update, page-19

First 19 Last

Share
Profile

Follow
Potato5

449 Posts.

46

18/07/22

13:15

Post #: 62588316
Share

Originally posted by tjames85: ↑

Looking at this simply

1. The business has had a $50M negative turnaround in EBITDA performance over the last 12 months ($10M EBITDA for FY22 vs $60.7M proforma EBITDA in FY21)
2. Around half of this negative performance is due to revenue declining (from $176M in FY21 to $151M in FY22)
3. This means that the other half in the EBITDA decline must be due to increasing costs
4. All of this was predictable if you'd looked closely at the results for the first half (see my earlier post in the AFR Changing Tack thread)
5. Underlying free cashflow (after non operational legal costs and trading losses in the near term (haha what a joke to exclude trading losses form your stated trading performance) and non capitalised R&D costs will be in the order of negative $25-30M
6. The cash at bank of $48M is actually a lot higher than I would have expected. My guess is that the company has factored its R&D claim and/or drawn down on the CBA Debt Facility, so Nuix's NET CASH position will be much lower
7. Its becoming abundantly clear that Nuix does not have sufficient cash to fund a $25-30M burn rate over the next 12 months. It will either need to reduce headcount significantly (and that will also come at a cost if it involves Australian based staff), undertake a capital raising (hard to see Macquarie or any other sophisticated investor throwing good money after bad) or the assets be sold off or placed into administration.
8. If the assets are sold off, we can only look on at a Hunger Games like scenario as the class action firms, former CEO, staff (I expect a employee class action is waiting in the wings) all fight to recover what they can from the dead carcass that was Nuix.

I repeat again WHERE IS ASIC? WHERE IS THE ASX? Is anybody home or are you going to drop the ball a second time....

Expand

ASIC dont want to get involved because the last time they did, it gave them a bad name.
ASX are just all talk. they suspend ISX but won't even do anything with this... what a joke... well i'll admit the ASX are losing key management staff by the day as well..

All in my opinion. DYOR.

NXL Price at posting: 64.0¢ Sentiment: None Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

BPM

BPM Minerals hits high-grade gold at the Claw Project WA; shares jump 86%

CXU

Cauldron discovers shallow uranium up to 2km at WA's Yanrey

HVN

Harvey Norman clocks subdued gains as Echo Law's junk warranty class action kicks off

PAR

FDA hands Paradigm Biopharma guidance to re-jig phase 3 osteo trial – or is it a delay?

88E

HotCopper users smell capital raising as 88 Energy says "significant update" at Phoenix

There are more pages in this discussion • 19 more messages in this thread...

First 19 Last

Add NXL (ASX) to my watchlist

(20min delay)
Last $5.51		Change 0.060(1.10%)		Mkt cap ! $1.806B

Open	High	Low	Value	Volume
$5.38	$5.53	$5.35	$7.467M	1.362M

Buyers (Bids)

No.	Vol.	Price($)
13	2806	$5.50

Sellers (Offers)

Price($)	Vol.	No.
$5.52	4753	10

View Market Depth

No.	Vol.	Price($)
8	2634	5.510
14	6028	5.500
12	15177	5.490
5	4281	5.480
7	4779	5.470

Price($)	Vol.	No.
5.520	1287	5
5.530	14612	13
5.540	6522	6
5.550	30945	9
5.560	27870	6

Last trade - 14.02pm 18/09/2024 (20 minute delay)

NXL (ASX) Chart

Ann: FY22 results update, page-19

BPM Minerals hits high-grade gold at the Claw Project WA; shares jump 86%

Cauldron discovers shallow uranium up to 2km at WA's Yanrey

Harvey Norman clocks subdued gains as Echo Law's junk warranty class action kicks off

FDA hands Paradigm Biopharma guidance to re-jig phase 3 osteo trial – or is it a delay?

HotCopper users smell capital raising as 88 Energy says "significant update" at Phoenix

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: FY22 results update, page-19

Top Stories

BPM Minerals hits high-grade gold at the Claw Project WA; shares jump 86%

Cauldron discovers shallow uranium up to 2km at WA's Yanrey

Harvey Norman clocks subdued gains as Echo Law's junk warranty class action kicks off

FDA hands Paradigm Biopharma guidance to re-jig phase 3 osteo trial – or is it a delay?

HotCopper users smell capital raising as 88 Energy says "significant update" at Phoenix

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News